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AbstrACt
Introduction Methamphetamine dependence is a 
growing public health concern. There is currently no 
pharmacotherapy approved for methamphetamine 
dependence. Lisdexamfetamine (LDX) dimesylate, used 
in the treatment of attention-deficit hyperactivity disorder 
and binge eating disorder, has potential as an agonist 
therapy for methamphetamine dependence, and possible 
benefits of reduced risk of aberrant use due to its novel 
formulation.
Methods and analysis A double-blind randomised 
controlled trial will be used to evaluate the efficacy of LDX 
in reducing methamphetamine use. The target sample 
is 180 participants with methamphetamine dependence 
of ≥2 years, using ≥14 days out of the previous 28, who 
have previously attempted but not responded to treatment 
for methamphetamine use. Participants will be randomly 
assigned to receive either a 15-week intervention 
consisting of induction (1 week of 150 mg LDX or placebo), 
maintenance (12 weeks of 250 mg LDX or placebo) and 
reduction (1 week of 150 mg LDX or placebo and 1 week 
of 50 mg LDX or placebo). All participants will be given 
access to four sessions of cognitive–behavioural therapy 
as treatment as usual and receive a 4-week follow-up 
appointment. The primary outcomes are efficacy (change 
from baseline in days of methamphetamine use by self-
report for the last 28 days at week 13 and urinalyses 
confirmation of methamphetamine use) and safety 
(treatment-related adverse events). Secondary outcomes 
are total number of days of self-report methamphetamine 
use over the 12-week active treatment, longest period 
of abstinence during treatment period, percentage of 
achieving ≥21 days abstinence, craving, withdrawal, 
dependence, retention, bloodborne virus transmission 
risk behaviour, criminal behaviour, as well measures of 
abuse liability, physical and mental health, other substance 
use, cognitive performance, psychosocial functioning, 
treatment retention and satisfaction. Additionally, the study 
will assess the cost-effectiveness of LDX relative to the 
placebo control.
Ethics and dissemination The study has been approved 
by the Human Research Ethics Committee of St. Vincent’s 
Hospital, Sydney, Australia (HREC/16/SVH/222). Contact the 
corresponding author for the full trial protocol.
trial registration number ACTRN12617000657325; Pre-
results.
bACkground 
Methamphetamine is a synthetic stimulant 
of growing global public health importance 
and an important contributor to the global 
burden of disease.1 There are an estimated 
34 million people worldwide who use the 
drug, and an estimated 17 million who are 
dependent on methamphetamine.2 
Australia has one of the highest documented 
rates of methamphetamine dependence in 
the world, with 160 000 people estimated to 
be dependent during 2013/2014.1 Meth-
amphetamine dependence is estimated to 
cost Australia around $A5 billion a year, an 
economic impact which could be reduced by 
strengths and limitations of this study
 ► The study design is a prospective, randomised con-
trolled trial.
 ► Strength in methods includes allocation conceal-
ment, blinding, compliance measuring, drop-out 
measuring and analyses of results by intention to 
treat.
 ► The fixed-dose design is a limitation; if efficacious, 
further dose–response relationship studies may be 
indicated.
 ► The duration of active treatment is limited to 12 
weeks; if efficacious, further studies will be needed 
to explore optimum duration of treatment and a re-
ducing regimen.
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effective treatments.3 4 Methamphetamine dependence 
is associated with a range of negative health outcomes 
including psychosis, depression, anxiety, bloodborne 
virus transmission, sexually transmissible infections, and 
cardiovascular and cerebrovascular events.5 These prob-
lems are most prevalent among people who use metham-
phetamine on a heavy or regular basis,6 highlighting the 
need for effective treatments for this group.
There is no approved medication for the treatment 
of methamphetamine dependence. The current stan-
dard treatment for methamphetamine dependence 
relies on psychosocial interventions, primarily cogni-
tive–behavioural therapy (CBT)-based approaches.7 Such 
approaches produce small to medium reductions in 
methamphetamine use in controlled studies (d=0.538). 
However, CBT approaches require a substantial invest-
ment by trained therapists, there is often poor engage-
ment with counselling by methamphetamine users, and 
cognitive impairment associated with severe methamphet-
amine dependence may limit CBT effectiveness.7 Poorer 
treatment outcomes are seen in methamphetamine users 
who use frequently (those using methamphetamine at 
least 15 days out of the previous 30 days at treatment 
entry), than in less frequent users,9 highlighting the 
need for more effective treatment approaches for such 
individuals.
Many authors have highlighted the potential role of 
substitution agonist treatment for methamphetamine 
dependence.10 The theoretical base for agonist prescrip-
tion is consistent with the rationale for existing agonist 
substitution for nicotine and opioid dependence. Agonist 
substitution therapies aim to replace harmful drug use 
with safer alternatives in terms of dose, route of admin-
istration and adverse effects. Long-acting agonists 
can reduce amphetamine withdrawal,11 craving12 and 
decrease the euphoriant and reinforcing effects of extra 
(illicit) stimulant use due to cross-tolerance.13 Agonist 
treatment also provides a framework for regular ongoing 
healthcare and psychosocial interventions with this high-
risk population, enabling patients to distance themselves 
from illicit drug networks and related crime.
Agonist therapies for methamphetamine depen-
dence show promise. A number of ‘weak’ stimulant 
agonist therapies have been studied, including methyl-
phenidate and modafinil.14 A recent systematic review 
showed no benefit over placebo for any of these medi-
cations, noting limitations in retention and power of 
published studies.15 Dexamphetamine (DXA), a more 
direct monoamine agonist that more closely mimics the 
effects of methamphetamine, has been used clinically 
for amphetamine and methamphetamine dependence 
in the UK (in doses ranging from 20 to 200 mg) for some 
time,16 17 and in New South Wales (NSW), Australia, 
since 2006, at doses up to 80 mg.18 This experience 
suggests DXA substitution treatment may be useful in 
retaining a difficult to engage group of severely depen-
dent methamphetamine users who do not respond to 
stand-alone psychosocial interventions. Previous studies 
from methamphetamine dependent19–21 subjects found 
no serious consequences of DXA in doses from 30 to 
110 mg/day.22
While a statistically significant benefit on methamphet-
amine use has not been established with DXA pharma-
cotherapy, feasibility has been demonstrated with 60 mg 
DXA/day (equivalent to 150 mg lisdexamfetamine).19 
Studies with sustained-release (SR)-DXA formulations 
have shown increased retention in treatment at up to 
110 mg SR-DXA/daily (mean dose of 80 mg SR-DXA 
daily),20 and decreased craving and withdrawal symp-
toms in a study using 60 mg SR-DXA.21 This latter study 
(n=60) with a treatment duration of 8 weeks concluded 
that further studies should test a longer treatment dura-
tion, that higher doses of DXA could be warranted due to 
possible physiological tolerance, and that larger sample 
sizes are required.21
Lisdexamfetamine, a pharmacologically inactive 
prodrug, is absorbed after oral administration and is 
hydrolysed to inactive l-lysine and active DXA by red 
blood cells.23 It has a slower onset, lower peak concen-
tration and longer duration of action than DXA.24 It is 
metabolised rapidly to DXA: the peak plasma concen-
tration occurs 3 hours after dosing. The plasma half-life 
(t½) of DXA is 10 hours,25 with plasma DXA concen-
trations reaching steady state at day 5 of once daily 
lisdexamfetamine dosing.24 There is no plasma accumu-
lation of lisdexamfetamine.24 The conversion time from 
lisdexamfetamine to DXA results in a more blunted 
effect on brain dopamine than immediate release 
DXA26 and, as a consequence, it has a more moderate 
reinforcing effect in self-administration studies due to 
the slower onset of peak effects than other stimulant 
drugs.27
Abuse liability studies of lisdexamfetamine with doses 
of up to 150 mg indicate it has significantly less propensity 
for abuse-related ‘liking’ when compared with DXA or 
diethylpropion.28 The lower abuse liability of lisdexamfet-
amine, due to its rate-limited hydrolysis, attenuated onset 
and intensity of amphetamine-like effects, and more 
moderate reinforcing properties thus reduce the need 
for supervised dosing.
There have been no published randomised controlled 
trials of lisdexamfetamine for methamphetamine depen-
dence. Mooney et al29 were unable to show a significant 
change in cocaine use, though the study used a lower 
dose of 70 mg lisdexamfetamine, and failed to reach its 
planned sample size. The maintenance dose of 250 mg 
lisdexamfetamine represents equivalence to current DXA 
regimens for methamphetamine dependence.30 This dose 
has also been tolerated by non-methamphetamine depen-
dent volunteers in a pharmacokinetic study,31 as well as in 
a study in participants with schizophrenia receiving anti-
psychotic pharmacotherapy.32 A recent safety dose-esca-
lating trial of methamphetamine dependent participants 
with high frequency of use33 successfully escalated 14 out 
of 16 participants to 250 mg lisdexamfetamine34).
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objECtIvEs
The objective of the current trial was to test the efficacy 
of lisdexamfetamine for reducing methamphetamine use 
among people with methamphetamine dependence, who 
had not previously responded to psychosocial treatments.
We hypothesise that treatment with oral lisdexamfet-
amine will result in significantly reduced methamphet-
amine use at 13 weeks compared with placebo in people 
who are dependent on methamphetamine. The primary 
objectives of the study are efficacy and safety of 250 mg 
of lisdexamfetamine in reducing methamphetamine use 
after 13 weeks of treatment. Secondary objectives are 
to examine the changes in physical and mental health, 
cognitive and psychosocial functioning and well-being 
between lisdexamfetamine and placebo groups, as well 
as differences in retention rates, craving and withdrawal 
symptoms, and severity of dependence. Other secondary 
objectives are to examine differences in bloodborne virus 
transmission risk behaviour, criminality and in use of 
alcohol and other drugs between groups, as well as the 
abuse liability profile of lisdexamfetamine and the cost-ef-
fectiveness of lisdexamfetamine relative to the placebo 
control.
MEthods
trial design
This project is a randomised double-blind placebo 
controlled fixed dose parallel design comparing a 12-week 
maintenance course of 250 mg lisdexamfetamine daily to 
placebo.
sample size
The sample size calculation is based on data from the 
existing NSW Stimulant Treatment Program clients30 
who meet the inclusion criteria. Such clients showed a 
reduction from a mean of 19 days of use out of 28 days 
at pretreatment to a mean of 9 days/28 days with SD 
of 9 days at 12 weeks post-treatment. To detect a mean 
difference of 4.5 days (9 days in control vs 4.5 days in the 
lisdexamfetamine group out of 28 days) at week 13 (12 
weeks post-treatment), assuming a pooled SD of 9 days 
(ie, d=0.5, a median clinically relevant effect size), with 
over 80% power at two-sided significance level of 0.05, a 
sample size of 126 (63 per group) is required.10 Conserva-
tively estimating a 30% attrition from research follow-up 
(previous trials have achieved follow-up of 81% at 12 
weeks,26 90 participants per group will be recruited—180 
in total.
Participants
This study is being conducted in sites experienced in 
delivering and evaluating interventions in people who are 
dependent on methamphetamine. The participating sites 
are located in NSW and South Australia (SA).
The study population is treatment-seeking adults 
with long-standing (≥12 months) methamphetamine 
dependence who have failed to respond to previous 
methamphetamine treatment attempts. Participants will 
be aged 18–65 years, meet International Statistical Clas-
sification of Diseases and Related Health Problems 10th 
Revision (ICD-10) criteria for methamphetamine depen-
dence and self-report methamphetamine use of ≥14 days 
out of the previous 28. Prior use of methamphetamine will 
be verified by urinalysis. Failure to respond to previous 
treatment is defined as relapse to dependent use within 
1 month of completing treatment. Participants must be 
willing and able to comply with study requirements, be 
able to store study medications securely, and be able to 
provide written, informed consent.
Exclusion criteria are sensitivity or previous adverse reac-
tion to lisdexamfetamine, concurrent use or use within 
the previous 14 days of medications with possible interac-
tion with lisdexamfetamine. Known contraindications for 
lisdexamfetamine are also exclusion criteria. Individuals 
with severe medical disorders, including cardiovascular 
disease, untreated hypertension and peripheral vascular 
disease, will be ineligible, as will those with severe psychi-
atric disorders. Those currently in counselling for meth-
amphetamine dependence or who have been prescribed 
DXA or modafinil (in the 4 weeks prior to assessment) 
will be ineligible. Other exclusion criteria are dependent 
use of alcohol or other drugs, exposure to another inves-
tigational drug within the 4 weeks prior to screening, 
unavailability for follow-up, pregnant or lactating women 
and receipt of current pharmacotherapy treatment for 
opioid dependence.
Four specialist outpatient stimulant treatment centres 
in NSW and SA will recruit participants. Potential partici-
pants will be prescreened in person or by telephone by a 
researcher, and if potentially eligible invited to attend for 
a formal eligibility assessment by a specialist in addiction 
medicine. The assessment schedule, including eligibility 
assessments, is outlined in table 1.
randomisation
Eligible participants will be randomised to receive either 
the lisdexamfetamine or a placebo medication (see 
figure 1). A computer-generated randomisation schedule 
has been developed by an independent statistician and 
uploaded to the study database. Randomisation will be 
performed by the trial site pharmacist within the study 
database. The randomisation component of the database 
has been safe guarded with specific user rights allowing 
only the trial site pharmacist, the statistician and the 
chair of the Independent Data and Safety Monitoring 
Committee (IDSMC) to access randomisation allocations. 
Study participants, investigators, clinical and research 
staff will be blinded to the treatment condition allocated 
to reduce the risk of bias. Emergency unbinding will be 
permitted if required for safety of a participant, ongoing 
safe conduct of the trial or in the case of pregnancy.
Intervention
Oral lisdexamfetamine dimesylate 50 mg capsules will be 
used to make up the prescribed study dose. Trial medications 
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will be obtained, prepacked in child resistant blister packs, 
stored and transported to participating sites by a contracted 
good manufacturing practice registered facility in accor-
dance with the Poisons and Therapeutic Goods Act 1966 
and the Poisons and Therapeutic Goods Regulation 2008.
The active drug (lisdexamfetamine dimesylate) and the 
placebo shall be provided in identical capsules to ensure 
the study blind.
Table 1 Assessments and procedures: eligible participants 
will be required to attend the clinic daily for the first 5 days of 
treatment
Demographics and baseline assessments
  Demographics Screening
  Medical screening Screening
  Substance use history and 
treatment
Screening
  Columbia Suicide Severity Rating 
Scale—screening (CSSRS)40
Screening
  Enriched Social Support Inventory Week 1
  Wender-Utah Rating Scale41 Week 1
Intervention and counselling
  Lisdexamfetamine or placebo Weeks 1–15
  Baker et al 4 sessions CBT35 Weeks 2–13 (4 
sessions at least 
2 weeks apart)
Efficacy and safety measures
  Timeline followback (all drugs—
past 28 days)42
Screening and weeks 
1, 5, 9, 13, 19
  Timeline followback 
(methamphetamine only—past 
7 days)
Weeks 2, 3, 4, 6, 7, 8, 
10, 11, 12, 14, 15
  Medication adherence43 Weeks 1–15 (two times 
per week)
  Treatment Satisfaction 
Questionnaire44 plus testing blind
Weeks 5, 9, 13, 19
  Adverse events Weeks 1–15 (two times 
per week) and week 19
  Urine drug screen Screening and weeks 
1–15 (two times per 
week)
  Vital signs (temperature, blood 
pressure, heart rate, respiratory 
rate)
Screening and weeks 
1–15 (two times per 
week)
  Concomitant medications Screening and weeks 
1– 15 (two times per 
week)
  ECG Screening and weeks 
5, 9, 13
  Pregnancy testing (if applicable) Screening and weeks 
1, 5, 9, 13
  Medical assessment— since last 
visit
Screening and weeks 
1, 5, 9, 13, 19
  CSSRS—since last visit 40 Screening and weeks 
1, 5, 9, 13, 19
  Brief Psychiatric Rating Scale—
four items45
Screening and weeks 
1, 5, 9, 13, 19
  Review by study doctor Weeks 1, 5, 9, 13 and 
last day of treatment
Measures of physical and mental health and cognitive and 
psychosocial functioning
  Patient Health Questionnaire-1546 Weeks 1, 5, 9, 13, 19
Continued
  Depression Anxiety Stress 
Scales-2147
Weeks 1, 5, 9, 13, 19
  WHO Quality of Life-BREF Weeks 1, 5, 9, 13, 19
  Insomnia Severity Index48 Weeks 1, 5, 9, 13, 19
Neurocognitive testing batteries 
(combinations of the following):
(MOCA),49 (WTAR),50 RAVLT,51–53 
RVIP,53 54 N-Back,55 trail making 
test,56–59 flankers,54 60 digit 
symbol61 62
Screening and weeks 
1, 5, 9, 13, 19
Measures of cravings, withdrawal and severity of 
dependence
  Amphetamine Withdrawal 
Questionnaire63
Weeks 1, 5, 9, 13, 19
  Visual Analogue Scale for 
cravings64
Weeks 1, 5, 9, 13, 19
  Severity of Dependence Scale65 Weeks 1, 5, 9, 13, 19
Measures of abuse liability, other drug use, risk behaviour 
and crime
  Drug Evaluation Questionnaire-5 Weeks 1, 5, 9, 13, 19
  Timeline followback (all drugs— 
past 28 days)42
Screening and weeks 
1, 5, 9, 13, 19
  Urine drug screen Weeks 1–15 (two times 
per week)
  Opiate Treatment Index-Injecting 
Practices (OTI-I)
Weeks 1, 5, 9, 13, 19
  OTI-Crime (OTI-C) Weeks 1, 5, 9, 13, 19
  Substance Use and Sex Index Weeks 1, 5, 9, 13, 19
Measures for the cost-effectiveness analysis
  EuroQol-5 dimension66 Weeks 1, 5, 9, 13, 19
  Health service utilisation Weeks 1, 5, 9, 13, 19
  Work Productivity Questionnaire67 Weeks 1, 5, 9, 13, 19
  OTI-C – additional questions Weeks 1, 5, 9, 13, 19
  Travel time and costs Week 5
On day 5, they will be provided with 2 days supply of study 
medication to take at home. 
For the remainder of the treatment period, participants will attend 
the clinic two times per week for supervised dosing, safety 
assessments, provision of urine sample and collection of take 
home doses. Research visits will occur every 4 weeks until week 
19.
CBT, Cognitive behavioural therapy; MOCA, Montreal Cognitive 
Assessment; RAVLT, Rey Auditory Verbal Learning Task; RVIP, 
Rapid Visual Information Processing; WTAR, Wechsler Test of Adult 
Reading. 
Table 1 Continued 
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Eligible participants enrolled in the study will 
commence with 7 days of 150 mg lisdexamfetamine or 
placebo daily (the induction phase).33 34 They will attend 
the clinic for the first 5 days for supervised administration 
of the study medication, recording of blood pressure, 
pulse and temperature, monitoring of adverse events and 
medication adherence counselling. On the fifth day, the 
participant will be provided with two additional doses 
self-administer orally once a day. If the induction phase 
is tolerated, the participant will progress to the 250 mg 
lisdexamfetamine/placebo 12-week maintenance phase.
During the maintenance phase, participants will visit 
the clinic two times per week for a nursing review where 
vital signs will be recorded, adverse events monitored and 
medication adherence counselling undertaken. On the 
visit days, the administration of the dose for that day will 
be observed by the study nurse and participants will be 
provided with 2 or 3 days supply of the lisdexamfetamine/
Figure 1 Trial schema: potential participants will be screened for eligibility. Individuals, who meet the eligibility criteria and 
provide written informed consent to participate, will be randomised to lisdexamfetamine (LDX) or a placebo medication. 
Treatment will be for 15 weeks with a follow visit 4 weeks post-treatment.
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placebo to take home for self-administration until the 
next clinic visit. Participants will be required to return 
study medication packs for pill counts. A urine sample 
will be provided at each of the two times per week visits, 
one of which will be randomly selected according to a 
predetermined randomised schedule and sent for testing 
at the end of the study for the presence of methamphet-
amine, and the other stored for future use. Once each 
week study personnel will collect self-reported metham-
phetamine use for the previous week.
Participants will undergo a medical review every 4 weeks 
during the maintenance phase (weeks 5, 9 and 13), as 
well as neurocognitive testing and questionnaire comple-
tion as outlined in table 1.
If the participant experiences a grade 2 or 3 adverse 
event at any time that is considered to be related to the 
study drug, the study doctor shall consult with the trial 
chairperson about the option of withholding one dose. If 
a dose is withheld the participant will be reviewed by the 
study doctor the following day, or sooner as clinically indi-
cated. If the adverse event is resolved the following day, 
the dose can be recommenced and the participant will be 
reviewed the subsequent day. If the adverse event is not 
resolved or recurs after recommencing, the study doctor 
will then consult with the trial chairperson with regard to 
ceasing the medication and withdrawing the participant 
from the treatment component of the study.
During the reduction phase the dose will be tapered so 
as to minimise any drug discontinuation effects. The dose 
will be reduced to 150 mg lisdexamfetamine or placebo 
daily for 1 week, then 50 mg lisdexamfetamine or placebo 
daily for 1 week and then ceased.
Lisdexamfetamine will not be available for the manage-
ment of methamphetamine dependence following 
completion of the study. However, ongoing treatment 
will be individualised to the participant and outlined in 
a treatment plan which will be developed at week 13 by 
the study doctor.
Subjects will have a follow-up visit 4 weeks after cessa-
tion of the reduction phase (week 19).
Participants will be reimbursed with a supermarket 
voucher (that cannot be spent on alcohol or cigarettes) at 
weeks 1, 5, 9, 13 and 19. Reimbursements will start at $A20 
and increase by $A10 each month until the follow-up visit.
All participants will be offered counselling representing 
best practice treatment as usual. This will consist of four 
sessions of CBT of up to 1 hour per session,35 specially 
designed for and validated in the study population and 
delivered by trained therapist who will receive supervision 
monthly.
In addition to safety concerns (including acute 
psychosis, suicidal or homicidal ideation) or pregnancy, 
participants may be withdrawn from the study if they are 
absent from study treatment for more than two consec-
utive weeks. They will also be withdrawn from the study 
if they become subject to drug testing for legal or occu-
pational reasons (due to the risk of unblinding to group 
allocation).
Participants who have discontinued protocol treatment 
will be offered the opportunity continue to participate 
in all remaining research interviews and assessments. 
For those participants who revoke their consent for the 
entire study, no further data will be collected from the 
participant.
statistical methods
All efficacy analyses will use an intention-to-treat (ITT) 
approach. ITT will be defined as all randomised patients 
who received at least one dose of the prescribed medica-
tion. The primary efficacy measure is the change from 
baseline in days of methamphetamine use self-reported 
for the last 28 days at week 13. A likelihood-based mixed 
model of repeated measures (MMRM) approach will 
be used for the primary efficacy analysis. The differ-
ence between two groups at week 13 will be the primary 
comparison, and differences at week 5, 9 and 19 will 
also be examined. No imputation of missing data will be 
performed under MMRM approach, the MMRM analysis 
makes use of all available data and is reliable for effect and 
SE estimates under missing at random (MAR) assump-
tion.36 Sensitivity analysis including baseline observation 
carried forward imputation will be performed to investi-
gate the robustness of results to the departure from MAR 
assumption.
Secondary measures of the intervention effect will 
include total number of days of self-report MA use over 
the 12-week active treatment period; longest period 
of abstinence during treatment period; percentage of 
achieving ≥21 days abstinence; percentage of MA nega-
tive urines 4 weeks prior to week 12; craving, withdrawal, 
dependence, retention, bloodborne virus transmission 
risk behaviour, criminal behaviour, as well measures of 
abuse liability, physical and mental health, other substance 
use, cognitive performance, psychosocial functioning and 
treatment satisfaction. Statistical analysis strategies (t-test, 
Mann-Whitney U test, X2 test, linear/generalised linear 
regression and mixed-model analysis) will be used for 
secondary outcomes based on the type and distribution 
of the outcome measures. Kaplan-Merrier curve, log rank 
test and Cox proportional hazard model will be applied 
in the time to event data analysis.
Analysis of urine drug screen (UDS) results will follow 
established techniques for similar drug trials (Treatment 
Effectiveness Score37), calculated as a proportion (%) of 
UDS negative for methamphetamine out of total of 12 
possible UDS (with missing tests counted as positive).
All patients enrolled in the study will be evaluated 
with respect to safety-related outcomes. Safety data will 
be analysed according to the treatment that the patients 
actually received. Safety analyses will include summaries 
of the incidence of all adverse events that are possibly or 
probably treatment related, that occur during the study 
treatment period or within 30 days of the last dose of 
study treatment.
Additionally, the study will assess the cost-effective-
ness of lisdexamfetamine relative to the placebo control. 
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The primary outcome will be quality-adjusted life years 
measured by the five-level version of the EuroQol five-di-
mensional (EQ-5D) descriptive system (EQ-5D-5L). Costs 
will include clinical resources, other healthcare, crime, 
productivity and personal costs. The costs will be summed 
and combined with the outcome measure, and the incre-
mental cost-effectiveness ratio calculated.
All tests of the treatment effect will be conducted at a 
two-sided alpha level of 0.05.
Interim analyses will be performed when the 50th 
patient has completed treatment or 6 months after the 
commencement of recruitment, whichever comes first.
An IDSMC will monitor the progress of the study with 
the aim of safeguarding trial participants by assessing 
the safety and efficacy of the drug being investigated in 
the trial. The IDSMC may recommend stopping the trial 
if the number and/or severity of adverse events justify 
discontinuation of the study; on the basis of a positive 
efficacy result only when the primary endpoint (meth-
amphetamine use) data are truly compelling and the risk 
of a false positive conclusion is acceptably low (p<0.001 
for primary endpoint); if accrual rates are too low and/
or that non-compliance is too great to provide adequate 
power for identifying the specified benefit; it becomes 
clear that successful completion of the study is not 
feasible.
data statement
Study data will be collected and managed using 
Research Electronic Data Capture (REDCap) tools 
hosted at Hunter New England Local Health District). 
REDCap38  is a secure, web-based application designed to 
support data capture for research studies, providing: (1) 
an intuitive interface for validated data entry; (2) audit 
trails for tracking data manipulation and export proce-
dures; (3) automated export procedures for seamless 
data downloads to common statistical packages and (4) 
procedures for importing data from external sources.
Ethics and dissemination
Prior to an individual’s participation in the trial, he/
she shall be fully informed about the research and given 
ample time and opportunity to inquire about details and 
decide whether or not to participate. If they agree to 
participate, they will be asked to sign the study-specific 
consent form. Participants will also be invited to consent 
for their urine samples to be stored for future research
To ensure anonymity and to limit disclosure, partici-
pants will be assigned a unique identifier at the time of 
randomisation. Results arising from the main study will 
be published in peer-reviewed journals, and disseminated 
at international conferences. Results will be reported in 
such a manner that participants will not be identifiable 
in any way.
All data will be considered the property of the trial 
chairperson who, in consultation with the trial manage-
ment committee, will be responsible for presentations 
and publications arising from this trial.
Patient involvement
The initial concept of investigating the use of lisdexamfe-
tamine in reducing methamphetamine use in people who 
are dependent on methamphetamine was proposed by a 
patient who prefers to be unnamed. No other patients 
were involved in setting the research question or the 
outcome measures, nor have they been involved in devel-
oping plans for design or implementation of the study.
dIsCussIon
This is the first phase III trial of lisdexamfetamine for 
methamphetamine dependence. The strength of this 
study is in its proposed sample size, powered to detect 
a medium effect size in between group differences 
in the primary outcome (days of methamphetamine 
use), using a higher dose of agonist medication (more 
than triple) used typically for the treatment of atten-
tion-deficit hyperactivity disorder. Participants will be 
closely monitored with two times per week clinic visits 
and nursing reviews and monthly medical reviews. 
Two times per week, dispensing will promote retention in 
the study, and prevent high drop-out rates experienced 
in other studies.39 The study protocol proposes to deliver 
the medication in an outpatient setting allowing partici-
pants take-home dosing to more closely mimic the service 
delivery situations in which the medication may be used 
and provide some indication. Limitations of the study 
include the fixed-dose design, active treatment restricted 
to 12 weeks and two times per week observed dosing. If 
efficacious further dose–response relationship studies 
may be indicated to explore optimum duration of treat-
ment and a reducing regimen. If successful the interven-
tion will provide a much needed therapeutic adjunct for 
people who are dependent on methamphetamine.
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